SteadyMed’s Treyvent Awarded Orphan Drug Designation from FDA

Author: Dainela Semedo
Date Published: January-2016
Source: Pulmonary Hypertension News

SteadyMed, Ltd., a company that develops products to treat orphan and high-value conditions with unmet parenteral delivery needs, recently announced that its lead product candidate, Trevyent® has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH).